Proteomic profiling to predict therapeutic response to anti-PD1 therapy in advanced melanoma – SWATH MS dataset - glycopeptides
Ontology highlight
ABSTRACT: MS-based proteomics based on data-independent acquisition / SWATH MS was used to study the response of melanoma patients to anti-PD1 therapy. Human serum samples were collected from patients at the start of their therapy and later categorized into responders and non-responders based on clinical outcome. Samples were subjected to glycocapture and glycopeptides were quantified by SWATH MS followed by analysis using mapDIA to protein levels.
INSTRUMENT(S): TripleTOF 5600
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Serum
DISEASE(S): Melanoma
SUBMITTER: Ludovic Gillet
LAB HEAD: Ruedi Aebersold
PROVIDER: PXD027933 | Pride | 2023-08-21
REPOSITORIES: Pride
ACCESS DATA